Answers are grounded in this paper and cite their sources.
Despite the approval of several novel targeted therapies since 2017, acute myeloid leukaemia (AML) remains a devastating disease with high rates of relapse and a dismal prognosis. The heterogeneity of AML and poor tolerance of chemotherapeutic agents by the elderly necessitates that further treatment options are required. Chimeric antigen receptor (CAR) T-cell therapy is a form of adoptive cell-transfer based immunotherapy that leverages the use of genetically modified T cells to direct antigen specific cytotoxicity. Anti-CD19 and anti-B-cell maturation antigen (BCMA) CAR T-cell therapy have demonstrated remarkable therapeutic efficacy in B cell lymphomas and leukaemias and in multiple myeloma respectively. However, the clinical utility of CAR T-cell therapy has not yet extended to other malignancies. In the case of AML, this has been particularly hindered by a lack of suitable targeting antigens that specifically eliminate leukaemic cells whilst sparing normal healthy haematopoietic stem/progenitor cells (HSPCs). In this review, we highlight the pertinent challenges and barriers to effective CAR T-cell therapy in AML, as well as recent strategies to overcome them.
No takes yet. Share an insight, caveat, or question.
Park et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: